BioNTech SE (22UA.F)
| Previous close | 80.15 |
| Open | 80.15 |
| Bid | 80.90 x N/A |
| Ask | 82.55 x N/A |
| Day's range | 80.15 - 82.75 |
| 52-week range | 77.50 - 116.00 |
| Volume | |
| Avg. volume | 1,313 |
| Market cap | 19.882B |
| Beta (5Y monthly) | 0.23 |
| PE ratio (TTM) | 21.54 |
| EPS (TTM) | 3.83 |
| Earnings date | 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 02 Jun 2022 |
| 1y target est | 334.89 |
The TelegraphWall Street plunges after US inflation shock
US stock markets plunged amid fears of stagflation in the American economy, which grew at its slowest pace in nearly two years just as inflation jumped.
- Reuters
UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
ReutersGlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
(Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
